Table 1.
Clinicopathological characteristics of the patient cohort.
| No. of patients | % of patients | |
|---|---|---|
| Healthy control | 24 | 42.1 |
| Ovarian borderline tumor | 2 | 3.5 |
| Ovarian cancer | 31 | 54.4 |
|
| ||
| Age (y) (n = 57) | ||
| <50 | 11 | 19.3 |
| ≥50 | 46 | 80.7 |
|
| ||
| Tumor Stage (FIGO)(n = 32) | ||
| I | 4 | 12.5 |
| II | 3 | 9.4 |
| III | 17 | 53.1 |
| IV | 8 | 25.0 |
|
| ||
| Tumor Grade (n = 28) | ||
| G1 | 1 | 3.6 |
| G2 | 9 | 32.1 |
| G3 | 18 | 64.3 |
|
| ||
| Histological subtype (n = 33) | ||
| Serous | 19 | 57.6 |
| Endometrioid | 7 | 21.2 |
| Clear cell | 1 | 3.0 |
| Transitional cell | 4 | 12.1 |
| Undifferentiated | 2 | 6.1 |
|
| ||
| Residual disease (n = 23) | ||
| < 1cm | 12 | 52.2 |
| ≥ 1cm | 11 | 47.8 |
|
| ||
| Preoperative CA125 (n = 53) | ||
| < 35 U/ml | 18 | 34.0 |
| ≥ 35 U/ml | 35 | 66.0 |
|
| ||
| Blood group (n = 52) | ||
| A | 22 | 42.3 |
| B | 9 | 17.3 |
| AB | 2 | 3.8 |
| 0 | 19 | 36.6 |